Global Pneumonia Therapeutics Market; By Therapeutics (Prevention Vaccine, Treatment Drugs and Oxygen Therapy), By Drug Class (Antibacterial Drugs (Macrolide, Quinolones, and Others), Antiviral Drugs and Antifungal Drugs), By Age Group (Paediatric, Adult
Description
Global Pneumonia Therapeutics Market; By Therapeutics (Prevention Vaccine, Treatment Drugs and Oxygen Therapy), By Drug Class (Antibacterial Drugs (Macrolide, Quinolones, and Others), Antiviral Drugs and Antifungal Drugs), By Age Group (Paediatric, Adult and Geriatric), By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP] and Ventilator-associated Pneumonia [VAP]), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, the Asia-Pacific, the Middle-East & Africa, and Latin America)Trend Analysis, Competitive Market Share & Forecast, 2018-2028
Global Pneumonia Therapeutics Market Scripting Impressive Growth– Projected to Reach Worth USD 25,659.6 Million by 2028
The global pneumonia therapeutics market is witnessing a promising growth, The growing healthcare expenditure across developed nations, such as Germany, Japan, Brazil, and the United States, demonstrates a growing investment toward clinical research and development, thus enabling the growth of the pneumonia therapeutics market…
A recent study by the strategic consulting and market research firm BlueWeave Consulting revealed that the global Pneumonia Therapeutics market was worth USD 14,804.2 million in 2021. The market is further anticipated to reach USD 25,659.6 million in 2028 with a significant CAGR of 8.3% during the forecast period, i.e., 2022-2028. The growing healthcare expenditure across developed nations like Germany, Japan, Brazil, and the United States demonstrates a growing investment toward clinical research and development, thus enabling the growth of the pneumonia therapeutics market. The growing geriatric population, increasing expenditure on healthcare, growing focus on prevention of diseases, and the presence of leading market players are some of the factors driving the growth of the global pneumonia therapeutics market. Additionally, the rising investment in the R&D of new medicines and treatment methods and increasing incident rate of pneumonia are expected to present lucrative opportunities for the growth of the global pneumonia therapeutics market during the forecast period.
Online Pharmacies Contributing to the Growth of the Global Pneumonia Therapeutics Market
Based on distribution channels, the global pneumonia therapeutics market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment was dominant in the distribution channel segment across the global pneumonia therapeutics market in 2021. On the other hand, the online pharmacies segment is anticipated to register the highest CAGR during the forecast period. Online pharmacies are proliferating due to various factors, including ease of ordering, the emergence of telemedicine, door-step delivery, and the ongoing COVID-19 pandemic. Additionally, the emergence of Omicron, a new COVID-19 variant, across the globe is expected to propel the growth of online pharmacies in the near future.
Growing Per Capita Income Across Major Developing Countries Offering Lucrative Opportunities to the Global Pneumonia Therapeutics Market
The growing per capita income across developing nations contributes to the growth of the expenditure earmarked toward healthcare. It has helped them enhance life expectancy and afford proper treatment for pneumonia and pneumococcal vaccines. The GDP per capita for Bangladesh grew 9.28% from 2018-2019, and as of December 2021, it surpassed that of India and Pakistan. The Chinese GDP per capita grew 2.40% and Nigeria registered 9.92% of its per capita income growth within the same period. Though the coronavirus-induced pandemic led to some decline, nations are projected to register a growing trend once they reach their pre-pandemic levels. Higher income levels correlate with higher quality healthcare and treatment demands. Due to the rising demand for treatment, many lucrative opportunities arise for the development of healthcare systems and research and development, thus offering some opportunities for the growth of the global pneumonia therapeutics market.
Community-Acquired Pneumonia Dominates The Global Pneumonia Therapeutics Market
Based on infection types, the global pneumonia therapeutics market is segmented into hospital-acquired Pneumonia [HAP], community-acquired Pneumonia [CAP], and ventilator-associated Pneumonia [VAP]. The CAP segment acquired the largest share in 2021, followed by HAP among these segments. According to the European Lung White Book by the European Respiratory Society, community-acquired pneumonia (CAP) is the leading infection-related cause of death in Europe. The growth of the CAP segment in the market is expected to be driven by this factor.
Impact of COVID-19 on the Global Pneumonia Therapeutics Market
The COVID-19 pandemic severely impacted every industry worldwide as the government authorities decided to undertake stringent measures to eradicate or curb the spread of the virus, along with lockdowns restrictions. The healthcare calamity led to the shut down of various industries, including the pharmaceutical companies. However, a few months after the initial lockdowns, the essential industries, including the pharmaceutical industries, started witnessing some discretion for keeping the societal structure from collapsing. The demand side of the market had also skyrocketed due to the growing number of pneumonia cases that the patients were experiencing due to the COVID-19. Further, some countries reported that 8 out of 10 individuals got pneumonia from COVID-19, escalating the severity of the disease and contributing to the death toll across the globe.
The mounting misery resulted in a growing demand for vaccines against pneumococcal disease, including those composed of the 1, 14, and 19A serotypes of protection against the bacterium Streptococcus pneumonia across Sub-Saharan Africa and other developing nations. With the increasing number of trials related to pneumococcal vaccines from Pfizer, AstraZeneca, and Merck, the likelihood of survival from pneumonia is expected to increase.
North America Dominates the Global Pneumonia Therapeutics Market
The global Pneumonia Therapeutics market is categorized into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. North America dominated the market with the highest shares in 2021. Pneumonia is one of the major health issues in the North American region. According to the Centers for Disease Control & Prevention (CDC), in 2018, more than 1.5 million Americans suffered from pneumonia and more than 40,000 lost their lives. CDC further states that the majority of the people affected by pneumonia in the United States are adults, while children are among the least affected age group. Nevertheless, pneumonia is the most common reason for hospitalization among US children.
According to the American Thoracis Society, U.S. adults admitted to hospital for pneumonia are second only to women giving birth to motherhood as a cause of hospital admissions. It also states that more than 1 million patients are admitted to hospitals each year due to pneumonia, and more than 50,000 of them die from this disease. Furthermore, the American Thoracic Society data also shows that viral pneumonia is the leading cause of hospitalization in infants among American infants. According to Statistics Canada, pneumonia and influenza contributed to 6,893 deaths in 2019 and were the 7th leading cause of death in Canada. One of the major factors driving the growth of the global pneumonia therapeutics market in the region is the high prevalence of pneumonia cases, which is forecast to continue during the forecast period.
Global Pneumonia Therapeutics Market- Competitive Landscape
The global pneumonia therapeutics market is moderately consolidated. The major companies in the global pneumonia therapeutics market include Sanofi S.A., Eli Lilly & Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Baxter International Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and other prominent players. Pfizer Inc. has been recognized as the biggest player in the global pneumonia therapeutics market in 2021.
Pfizer Inc. has been a pioneer in the manufacturing of pneumonia vaccines, and the company's flagship PREVNAR 13 vaccine has helped them capture the largest share in the market. This vaccine can be administered to children from the age of 6 weeks up to 18 years old. The vaccine designed for 18 years of age or older adults is intended for active immunization and prevention of pneumonia and other invasive diseases, which are caused by S. pneumoniae serotypes, including 1, 4, 3, 5, 6B, 6A, 7F, 9V, 14, 19A and others.
Global Pneumonia Therapeutics Market Scripting Impressive Growth– Projected to Reach Worth USD 25,659.6 Million by 2028
The global pneumonia therapeutics market is witnessing a promising growth, The growing healthcare expenditure across developed nations, such as Germany, Japan, Brazil, and the United States, demonstrates a growing investment toward clinical research and development, thus enabling the growth of the pneumonia therapeutics market…
A recent study by the strategic consulting and market research firm BlueWeave Consulting revealed that the global Pneumonia Therapeutics market was worth USD 14,804.2 million in 2021. The market is further anticipated to reach USD 25,659.6 million in 2028 with a significant CAGR of 8.3% during the forecast period, i.e., 2022-2028. The growing healthcare expenditure across developed nations like Germany, Japan, Brazil, and the United States demonstrates a growing investment toward clinical research and development, thus enabling the growth of the pneumonia therapeutics market. The growing geriatric population, increasing expenditure on healthcare, growing focus on prevention of diseases, and the presence of leading market players are some of the factors driving the growth of the global pneumonia therapeutics market. Additionally, the rising investment in the R&D of new medicines and treatment methods and increasing incident rate of pneumonia are expected to present lucrative opportunities for the growth of the global pneumonia therapeutics market during the forecast period.
Online Pharmacies Contributing to the Growth of the Global Pneumonia Therapeutics Market
Based on distribution channels, the global pneumonia therapeutics market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment was dominant in the distribution channel segment across the global pneumonia therapeutics market in 2021. On the other hand, the online pharmacies segment is anticipated to register the highest CAGR during the forecast period. Online pharmacies are proliferating due to various factors, including ease of ordering, the emergence of telemedicine, door-step delivery, and the ongoing COVID-19 pandemic. Additionally, the emergence of Omicron, a new COVID-19 variant, across the globe is expected to propel the growth of online pharmacies in the near future.
Growing Per Capita Income Across Major Developing Countries Offering Lucrative Opportunities to the Global Pneumonia Therapeutics Market
The growing per capita income across developing nations contributes to the growth of the expenditure earmarked toward healthcare. It has helped them enhance life expectancy and afford proper treatment for pneumonia and pneumococcal vaccines. The GDP per capita for Bangladesh grew 9.28% from 2018-2019, and as of December 2021, it surpassed that of India and Pakistan. The Chinese GDP per capita grew 2.40% and Nigeria registered 9.92% of its per capita income growth within the same period. Though the coronavirus-induced pandemic led to some decline, nations are projected to register a growing trend once they reach their pre-pandemic levels. Higher income levels correlate with higher quality healthcare and treatment demands. Due to the rising demand for treatment, many lucrative opportunities arise for the development of healthcare systems and research and development, thus offering some opportunities for the growth of the global pneumonia therapeutics market.
Community-Acquired Pneumonia Dominates The Global Pneumonia Therapeutics Market
Based on infection types, the global pneumonia therapeutics market is segmented into hospital-acquired Pneumonia [HAP], community-acquired Pneumonia [CAP], and ventilator-associated Pneumonia [VAP]. The CAP segment acquired the largest share in 2021, followed by HAP among these segments. According to the European Lung White Book by the European Respiratory Society, community-acquired pneumonia (CAP) is the leading infection-related cause of death in Europe. The growth of the CAP segment in the market is expected to be driven by this factor.
Impact of COVID-19 on the Global Pneumonia Therapeutics Market
The COVID-19 pandemic severely impacted every industry worldwide as the government authorities decided to undertake stringent measures to eradicate or curb the spread of the virus, along with lockdowns restrictions. The healthcare calamity led to the shut down of various industries, including the pharmaceutical companies. However, a few months after the initial lockdowns, the essential industries, including the pharmaceutical industries, started witnessing some discretion for keeping the societal structure from collapsing. The demand side of the market had also skyrocketed due to the growing number of pneumonia cases that the patients were experiencing due to the COVID-19. Further, some countries reported that 8 out of 10 individuals got pneumonia from COVID-19, escalating the severity of the disease and contributing to the death toll across the globe.
The mounting misery resulted in a growing demand for vaccines against pneumococcal disease, including those composed of the 1, 14, and 19A serotypes of protection against the bacterium Streptococcus pneumonia across Sub-Saharan Africa and other developing nations. With the increasing number of trials related to pneumococcal vaccines from Pfizer, AstraZeneca, and Merck, the likelihood of survival from pneumonia is expected to increase.
North America Dominates the Global Pneumonia Therapeutics Market
The global Pneumonia Therapeutics market is categorized into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. North America dominated the market with the highest shares in 2021. Pneumonia is one of the major health issues in the North American region. According to the Centers for Disease Control & Prevention (CDC), in 2018, more than 1.5 million Americans suffered from pneumonia and more than 40,000 lost their lives. CDC further states that the majority of the people affected by pneumonia in the United States are adults, while children are among the least affected age group. Nevertheless, pneumonia is the most common reason for hospitalization among US children.
According to the American Thoracis Society, U.S. adults admitted to hospital for pneumonia are second only to women giving birth to motherhood as a cause of hospital admissions. It also states that more than 1 million patients are admitted to hospitals each year due to pneumonia, and more than 50,000 of them die from this disease. Furthermore, the American Thoracic Society data also shows that viral pneumonia is the leading cause of hospitalization in infants among American infants. According to Statistics Canada, pneumonia and influenza contributed to 6,893 deaths in 2019 and were the 7th leading cause of death in Canada. One of the major factors driving the growth of the global pneumonia therapeutics market in the region is the high prevalence of pneumonia cases, which is forecast to continue during the forecast period.
Global Pneumonia Therapeutics Market- Competitive Landscape
The global pneumonia therapeutics market is moderately consolidated. The major companies in the global pneumonia therapeutics market include Sanofi S.A., Eli Lilly & Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Baxter International Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and other prominent players. Pfizer Inc. has been recognized as the biggest player in the global pneumonia therapeutics market in 2021.
Pfizer Inc. has been a pioneer in the manufacturing of pneumonia vaccines, and the company's flagship PREVNAR 13 vaccine has helped them capture the largest share in the market. This vaccine can be administered to children from the age of 6 weeks up to 18 years old. The vaccine designed for 18 years of age or older adults is intended for active immunization and prevention of pneumonia and other invasive diseases, which are caused by S. pneumoniae serotypes, including 1, 4, 3, 5, 6B, 6A, 7F, 9V, 14, 19A and others.
Table of Contents
226 Pages
- 1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
- 2. Research Methodology
- 2.1. Qualitative Research
- 2.1.1. Primary & Secondary Research
- 2.2. Quantitative Research
- 2.3. Market Breakdown & Data Triangulation
- 2.3.1. Primary & Secondary Research End-use Vendors
- 2.3.2. Secondary Research
- 2.3.3. Primary Research
- 2.4. Breakdown of Primary Research Respondents, By Region
- 2.5. Assumption & Limitation
- 3. Executive Summary
- 4. Global Pneumonia Therapeutics Market Insights
- 4.1. Industry Value Chain Analysis
- 4.2. DROC Analysis
- 4.2.1. Growth Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunities
- 4.2.4. Challenges
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining End-use Industry of Suppliers
- 4.3.2. Bargaining End-use Industry of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Intensity of Rivalry
- 4.4. Recent Development/ Technological Advancement
- 4.5. Regulatory Insights
- 5. Global Pneumonia Therapeutics Market Overview
- 5.1. Market Size & Forecast by Value, 2018-2028
- 5.1.1. By Value (USD Million)
- 5.2. Market Share & Forecast
- 5.2.1. By Therapeutics
- 5.2.1.1. Prevention Vaccine
- 5.2.1.2. Treatment Drugs
- 5.2.1.3. Oxygen Therapy
- 5.2.2. By Drug Class
- 5.2.2.1. Antibacterial Drugs
- 5.2.2.1.1. Macrolide
- 5.2.2.1.2. Quinolones
- 5.2.2.1.3. Others
- 5.2.2.2. Antiviral Drugs
- 5.2.2.3. Antifungal Drugs
- 5.2.3. By Age Group
- 5.2.3.1. Paediatric
- 5.2.3.2. Adult
- 5.2.3.3. Geriatric
- 5.2.4. By Infection Type
- 5.2.4.1. Hospital-acquired Pneumonia [HAP]
- 5.2.4.2. Community-acquired Pneumonia [CAP]
- 5.2.4.3. Ventilator-associated Pneumonia [VAP]
- 5.2.5. By Distribution Channel
- 5.2.5.1. Hospital Pharmacies
- 5.2.5.2. Retail Pharmacies
- 5.2.5.3. Online Pharmacies
- 5.2.6. By Region
- 5.2.3.1. North America
- 5.2.3.2. Europe
- 5.2.3.3. Asia-Pacific
- 5.2.3.4. Latin America
- 5.2.3.5. Middle East and Africa
- 6. North Pneumonia Therapeutics Market
- 6.1. Market Size & Forecast by Value, 2018-2028
- 6.1.1. By Value (USD Million)
- 6.2. Market Share & Forecast
- 6.2.1. By Therapeutics
- 6.2.2. By Drug Class
- 6.2.3. By Age Group
- 6.2.4. By Infection Type
- 6.2.5. By Distribution Channel
- 6.2.6. By Country
- 6.2.6.1. U.S.
- 6.2.6.2. Canada
- 7. Europe Pneumonia Therapeutics Market
- 7.1. Market Size & Forecast by Value, 2018-2028
- 7.1.1. By Value (USD Million)
- 7.2. Market Share & Forecast
- 7.2.1. By Therapeutics
- 7.2.2. By Drug Class
- 7.2.3. By Age Group
- 7.2.4. By Infection Type
- 7.2.5. By Distribution Channel
- 7.2.6. By Country
- 7.2.6.1. France
- 7.2.6.2. Germany
- 7.2.6.3. Italy
- 7.2.6.4. Spain
- 7.2.6.5. Rest of Europe
- 8. The Asia-Pacific (APAC) Pneumonia Therapeutics Market
- 8.1. Market Size & Forecast by Value, 2018-2028
- 8.1.1. By Value (USD Million)
- 8.2. Market Share & Forecast
- 8.2.1. By Therapeutics
- 8.2.2. By Drug Class
- 8.2.3. By Age Group
- 8.2.4. By Infection Type
- 8.2.5. By Distribution Channel
- 8.2.6. By Country
- 8.2.6.1. Japan
- 8.2.6.2. China
- 8.2.6.3. India
- 8.2.6.4. South Korea
- 8.2.6.5. Rest of APAC
- 9. Latin America Pneumonia Therapeutics Market
- 9.1. Market Size & Forecast by Value, 2018-2028
- 9.1.1. By Value (USD Million)
- 9.2. Market Share & Forecast
- 9.2.1. By Therapeutics
- 9.2.2. By Drug Class
- 9.2.3. By Age Group
- 9.2.4. By Infection Type
- 9.2.5. By Distribution Channel
- 9.2.6. By Country
- 9.2.6.1. Brazil
- 9.2.6.2. Argentina
- 9.2.6.3. Mexico
- 9.2.6.4. Rest of Latin America
- 10. The Middle East & Africa (MEA) Pneumonia Therapeutics Market
- 10.1. Market Size & Forecast by Value, 2018-2028
- 10.1.1. By Value (USD Million)
- 10.2. Market Share & Forecast
- 10.2.1. By Therapeutics
- 10.2.2. By Drug Class
- 10.2.3. By Age Group
- 10.2.4. By Infection Type
- 10.2.5. By Distribution Channel
- 10.2.6. By Country
- 10.2.6.1. South Africa
- 10.2.6.2. Saudi Arabia
- 10.2.6.3. U.A.E.
- 10.2.6.4. Rest of MEA
- 11. Competitive Landscape
- 11.1. List of Key Players and their Offerings
- 11.2. Company Market Share Analysis, 2021
- 11.3. Competitive Benchmarking, By Operating Parameters
- 12. Impact of Covid-19 across Global Pneumonia Therapeutics Market
- 13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
- 13.1. Merck & Co, Inc
- 13.2. Sanofi SA
- 13.3. AstraZeneca plc
- 13.4. Eli Lilly and Company
- 13.5. Teva Pharmaceutical Industries Ltd
- 13.6. Abbvie Inc
- 13.7. Novartis International AG
- 13.8. Abbott Laboratories
- 13.9. Bayer AG
- 13.10. Pfizer Inc
- 13.11. GlaxoSmithKline Plc
- 13.12. Lupin Pharmaceuticals, Inc
- 14. Key Strategic Recommendations
- *Financial details of unlisted companies will be available as per data availability in the final deliverable
- **The segmentation and the companies are subjected to modifications based on the in-depth secondary for the final deliverable
- List of figures
- Fig 1: Global Pneumonia Therapeutics Market Segmentation
- Fig 2: Global Pneumonia Therapeutics Market Size, By Value (USD Million)
- Fig 3: Global Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value (in %), 2021
- Fig 4: Global Pneumonia Therapeutics Market Industry Value Chain Analysis
- Fig 5: Global Pneumonia Therapeutics Market Industry Players
- Fig 6: Global Pneumonia Therapeutics Market Share: Market Share Analysis, 2021
- Fig 7: Porters Five Forces Analysis
- Fig 8: Global Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 9: Global Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 10: Global Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 11: Global Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 12: Global Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 13: Global Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 14: Global Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 15: Global Pneumonia Therapeutics Market Share (%), By Region, By Value, 2018-2028
- Fig 16: North America Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 17: North America Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 18: North America Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 19: North America Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 20: North America Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 21: North America Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 22: North America Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 23: North America Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028
- Fig 24: Europe Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 25: Europe Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 26: Europe Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 27: Europe Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 28: Europe Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 29: Europe Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 30: Europe Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 31: Europe Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028
- Fig 32: Asia-Pacific Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 33: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 34: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 35: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 36: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 37: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 38: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 39: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028
- Fig 40: Latin America Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 41: Latin America Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 42: Latin America Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 43: Latin America Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 44: Latin America Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 45: Latin America Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 46: Latin America Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 47: Latin America Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028
- Fig 48: Middle East & Africa Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028
- Fig 49: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028
- Fig 50: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028
- Fig 51: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Fig 52: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028
- Fig 53: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028
- Fig 54: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028
- Fig 55: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028
- List of Tables
- Table 1: Global Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 2: Global Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 3: Global Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 4: Global Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 5: Global Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 6: Global Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 7: Global Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 8: North America Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 9: North America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 10: North America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 11: North America Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 12: North America Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 13: North America Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 14: North America Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 15: Europe Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 16: Europe Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 17: Europe Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 18: Europe Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 19: Europe Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 20: Europe Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 21: Europe Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 22: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 23: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 24: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 25: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 26: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 27: Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 28: Asia-Pacific Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 29: Latin America Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 30: Latin America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 31: Latin America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 32: Latin America Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 33: Latin America Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 34: Latin America Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 35: Latin America Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 36: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028
- Table 37: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028
- Table 38: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028
- Table 39: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028
- Table 40: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028
- Table 41: Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028
- Table 42: Middle East & Africa Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028
- Table 43: Merck & Co., Inc. Company Overview
- Table 44: Merck & Co. Financial Analysis (USD Million)
- Table 45: Sanofi S.A. Company Overview
- Table 46: Sanofi S.A Financial Analysis (USD Million)
- Table 47: AstraZeneca plc Company Overview
- Table 48: AstraZeneca plc Financial Analysis (USD Million)
- Table 49: Eli Lilly and Company Overview
- Table 50: Eli Lilly and Company Financial Analysis (USD Million)
- Table 51: Teva Pharmaceutical Industries Ltd. Company Overview
- Table 52: Teva Pharmaceutical Financial Analysis (USD Million)
- Table 53: Abbvie Inc. Company Overview
- Table 54: Abbvie Inc. Financial Analysis (USD Million)
- Table 55: Novartis International AG Company Overview
- Table 56: Novartis International AG Financial Analysis (USD Million)
- Table 57: Abbott Laboratories Company Overview
- Table 58: Abbott Laboratories Financial Analysis (USD Million)
- Table 59: Bayer AG Company Overview
- Table 60: Bayer AG Financial Analysis (USD Million)
- Table 61: Pfizer Inc. Company Overview
- Table 62: Pfizer Inc. Financial Analysis (USD Million)
- Table 63: GlaxoSmithKline Plc. Limited Company Overview
- Table 64: GlaxoSmithKline Plc. Financial Analysis (USD Million)
- Table 65: Lupin Pharmaceuticals, Inc., Company Overview
- Table 66: Lupin Pharmaceuticals, Inc., Financial Analysis (USD Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
